S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
This Stock Could Go Up 66% or More. (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
This Stock Could Go Up 66% or More. (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
This Stock Could Go Up 66% or More. (Ad)
Canadian autoworkers ratify new labor agreement with Ford
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
NASDAQ:ATHE

Alterity Therapeutics (ATHE) Stock Forecast, Price & News

$2.65
+0.02 (+0.76%)
(As of 09/22/2023 08:51 PM ET)
Compare
Today's Range
$2.65
$2.65
50-Day Range
$2.56
$2.95
52-Week Range
$2.52
$5.10
Volume
300 shs
Average Volume
13,193 shs
Market Capitalization
$10.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Alterity Therapeutics MarketRank™ Forecast

Analyst Rating
0.00 Rating Score
Upside/​Downside
277.4% Upside
$10.00 Price Target
Short Interest
Healthy
0.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.52) to ($0.29) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

832nd out of 962 stocks

Biotechnology Industry

13th out of 19 stocks


ATHE stock logo

About Alterity Therapeutics (NASDAQ:ATHE) Stock

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

ATHE Price History

ATHE Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Appendix 4C – Q4 FY23 Quarterly Cash Flow Report
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Appendix 4C – Q3 FY23 Quarterly Cash Flow Report
Appendix 4C - Q2 FY23 Quarterly Cash Flow Report
See More Headlines
Receive ATHE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATHE Company Calendar

Today
9/24/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATHE
Employees
11
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+277.4%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.37 million
Book Value
$3.83 per share

Miscellaneous

Free Float
2,455,000
Market Cap
$10.63 million
Optionable
Not Optionable
Beta
1.16
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Geoffrey Paul Kempler B.Sc (Age 68)
    B.Sc., Co-Founder & Non-Exec. Chairman
    Comp: $201.39k
  • Dr. David A. Stamler M.D. (Age 62)
    Chief Exec. Officer
    Comp: $595.2k
  • Ms. Kathryn J. E. Andrews (Age 56)
    Chief Financial Officer
    Comp: $210.47k
  • Dr. Rudolph Emile Tanzi Ph.D. (Age 64)
    Chief Scientific Advisor and Member of R&D Advisory Board
  • Dr. Steven D. Targum
    Chief Medical Advisor
  • Dr. Robert Cherny
    Head of Research
  • Mr. Phillip Allen Hains BBus(Acc) (Age 64)
    C.A., CA, M.B.A., MBA, Company Sec.













ATHE Stock - Frequently Asked Questions

What is Alterity Therapeutics' stock price forecast for 2023?

0 brokers have issued twelve-month price targets for Alterity Therapeutics' shares. Their ATHE share price forecasts range from $10.00 to $10.00. On average, they anticipate the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 277.4% from the stock's current price.
View analysts price targets for ATHE
or view top-rated stocks among Wall Street analysts.

How have ATHE shares performed in 2023?

Alterity Therapeutics' stock was trading at $3.4820 at the beginning of the year. Since then, ATHE stock has decreased by 23.9% and is now trading at $2.65.
View the best growth stocks for 2023 here
.

Are investors shorting Alterity Therapeutics?

Alterity Therapeutics saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 16,700 shares, a drop of 13.0% from the August 15th total of 19,200 shares. Based on an average daily trading volume, of 4,300 shares, the days-to-cover ratio is currently 3.9 days. Currently, 0.4% of the shares of the company are short sold.
View Alterity Therapeutics' Short Interest
.

When did Alterity Therapeutics' stock split?

Shares of Alterity Therapeutics reverse split before market open on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Alterity Therapeutics own?
What is Alterity Therapeutics' stock symbol?

Alterity Therapeutics trades on the NASDAQ under the ticker symbol "ATHE."

How do I buy shares of Alterity Therapeutics?

Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alterity Therapeutics' stock price today?

One share of ATHE stock can currently be purchased for approximately $2.65.

How much money does Alterity Therapeutics make?

Alterity Therapeutics (NASDAQ:ATHE) has a market capitalization of $10.63 million and generates $3.37 million in revenue each year.

How can I contact Alterity Therapeutics?

Alterity Therapeutics' mailing address is LEVEL 3 460 BOURKE STREET, MELBOURNE C3, VIC 3000. The official website for the company is www.alteritytherapeutics.com. The company can be reached via phone at (139) 349-4906, via email at alterity@we-buchan.com, or via fax at 61-3-9348-0377.

This page (NASDAQ:ATHE) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -